Table 1 Cohort demographics

From: Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

  

GI

Fatigue

Cardiorespiratory

Anxiety/depression

Cognitive impairment

Recovered

P value

Age at admission

Years (s.d.)

57.72 (11.48)

56.57 (11.07)

57.08 (11.37)

56.36 (10.84)

59.24 (12.82)

58.92 (13.72)

0.046 *

Sex

Female N (%)

68 (53%)

143 (47%)

161 (43%)

89 (45%)

24 (42%)

55 (27%)

1.69 × 10−6****

Ethnicity

White

110

300

331

193

50

197

0.09 NS

South Asian

14

26

38

16

7

46

Black

8

16

25

11

7

10

Mixed/Other

8

24

22

16

7

17

WHO clinical progression scale for acute COVID-19

Class 3–4

41

83

88

45

18

45

0.28 NS

Class 5

45

107

124

74

21

115

Class 6

27

78

89

55

11

57

Class 7–9

27

98

115

62

21

50

CRP

Mean (s.d.)

5.33 (5.42)

5.47 (7.17)

5.17 (6.82)

5.79 (8.12)

4.58 (5.78)

4.75 (10.38)

0.76 NS

Length of hospitalization

Days (s.d.)

12.04 (14.3)

14.59 (18.41)

15.39 (19.96)

14.57 (17.76)

14.95 (16.01)

12.5 (15.73)

0.0047**

Steroida

% Yes

34%

35%

37%

38%

33%

29%

0.294 NS

Remdesivira

% Yes

4%

3%

4%

2%

3%

3%

0.725 NS

Comorbidities

Mean (s.d.)

2.9 (2.62)

2.675 (2.3)

2.553 (2.24)

2.911 (2.47)

2.493 (2.17)

1.554 (1.67)

9.92 × 10−10****

  1. The demographics of each symptom group and recovered controls are shown. The WHO clinical progression scale was used to classify acute COVID-19 severity: class 3–4: no oxygen requirement; class 5: oxygen therapy; class 6: noninvasive ventilation or high-flow nasal oxygen and class 7–9: organ support. Differences between groups were compared using chi-squared, two-way Kruskal–Wallis or two-way analysis of variance as appropriate. Data are n (%) or mean (s.d.). CRP levels represent those measured contemporaneously with clinical data collected in this study.
  2. aDenotes treatment given during acute illness.
Back to article page